In contrast, the MATTERHORN trial incorporated durvalumab into perioperative FLOT chemotherapy in resectable, HER2-negative gastric and GEJ adenocarcinoma but enrolled an unselected, all-comer population regardless of MSI status. Here, ERBB2 is linked to gastroesophageal junction adenocarcinoma.